Validation of a spectrophotometric method for quantification of xanthone in biodegradable nanoparticles

Pharmazie

Volumn 59, Issue 4, 2004, Pages 257-259

  Teixeira, M ^a,b   Pinto, M M M ^a   Gonçalves Barbosa, Carlos Mauricio ^a,c  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY INSTITUTE OF HEALTH SCIENCES IUCS   (Portugal)

^c CETMED Ctro Tecn do Medicamento   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

EXCIPIENT; NANOPARTICLE; POLYGLACTIN; XANTHONE DERIVATIVE;

ACCURACY; ARTICLE; BIODEGRADABILITY; CALIBRATION; CONCENTRATION (PARAMETERS); PRACTICE GUIDELINE; QUANTITATIVE ANALYSIS; RELIABILITY; SPECTROPHOTOMETRY; VALIDATION PROCESS;

CALIBRATION; CHROMATOGRAPHY, THIN LAYER; LACTIC ACID; MICROSPHERES; PARTICLE SIZE; POLYGLYCOLIC ACID; POLYMERS; REPRODUCIBILITY OF RESULTS; XANTHONES;

EID: 1842683160     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Calpena CA, Escribano FE, Fernández LC (1990) Validación de los métodos analíticos. Farm Clín 7: 749-758.
2. Chen CH, Lin JY (1992) Inhibition of angiotensine-I-converting enzyme by tetrahydroxyxanthones isolated from Tripterospermum lanceolatum. J Nat Prod 55: 691-695.
3. Fernandes ER, Carvalho FD, Remião FG, Bastos ML, Pinto M, Gottlieb OR (1995) Hepatoprotective activity of xanthones and xanthonolignoids against tert-butylhydroperoxide-induced toxicity in isolated rat hepatocytes - comparison with silybin. Pharm Res 12: 1756-1760.
4. Fessi H, Puisieux F, Devissaguet JPh, Ammoury N, Benita S (1989) Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm 55: R1-R4.
5. Gnerre C, Thull U, Gaillard P, Carrupt P-A, Testa B, Fernandes E, Silva F, Pinto M, Pinto MMM, Wolfender J-L-, Hostettmann K, Cruciani G (2001) Natural and synthetic xanthones as monoaminoxidase inhibitors: biological assays and 3D-QSAR Helv Chim Acta 84: 552-570.
6. Gonzalez MJ, Nascimento MSJ, Cidade H, Pinto MM, Kijjoa A, Anantachoke C, Silva AMS, Herz W (1999) Immunomodulatory activity of xanthones from Calophyllum teysmannii var. inuphylloide. Planta Med 65: 368-371.
7. Hnuma M, Tosa H, Asai F, Kobayashi Y, Shimano R, Miyandis KI (1996) Antibacterial activity of xanthones from Guttiferaeous plants against methicillin-resistant Staphylococcus aureus. J Pharm Pharmacol 48: 861-865.
8. Ignatushchenko MV, Winter RW, Bachinger HP, Hinrich DJ, Riscoe MK (1997) Xanthones as antimalarial agents; studies of a possible mode of action. FEBS Lett 409: 67-73.
9. Jain R, Shah NH, Malick AW, Rhodes C (1998) Controlled drug delivery by biodegradable poly(ester) devices: different preparative approaches. Drug Dev Ind Pharm 24: 703-727.
10. Kamei H, Koide T, Kojima T, Hashimoto J, Hasegawa Y (1998) Inhibition of cell growth in culture by quinones. Cancer Biother Radiopharm 13: 185-188.
11. Lin CN, Chung MI, Liou SJ, Lee TH, Wang JP (1996b) Synthesis and anti-inflammatory effects of xanthone derivatives. J Pharm Pharmacol 48: 532-538.
12. Lin CN, Liou SJ, Lee TH, Chuang YC, Won SJ (1996a) Xanthone derivatives as potential anti-cancer drugs. J Pharm Pharmacol 48: 539-544.
13. Mehta AC (1989) The validation criteria for analytical methods used in pharmacy practice research. J Clin Pharm Ther 14: 465-473.
14. Peres V, Nagem TJ, de Oliveira FF (2000) Tetraoxygenated naturally occurring xanthones. Phytochemistry 55: 683-710.
15. Pinto M, Nascimento MSJ (1997) Anticomplementary activity of hydroxy-and methoxyxanthones. Pharm Pharmacol Lett 7: 125-127.
16. Speiser P (1981). Poorly soluble drugs, a challenge in drug delivery. In: Müller RH, Benita S, Böhm B (Eds) Emulsions and nanosuspensions for the formulation of poorly soluble drugs, Scientific Pub., Stuttgart, pp. 15-19.
17. Thull U, Testa B (1994) Screening of unsubstituted cyclic compounds as inhibitors of monoamino oxidases. Biochem Pharmacol 47: 2307-2310.
18. Thull U, Kneuber S, Testa B, Borges MFM, Pinto MM (1993) Pharm Res 10: 1187-1190.
19. United States Pharmacopeia 25/NF 20 (2002). United States Pharmacopeial Convention, Rockville, MD, pp. 2256-2259.
20. Validation of Analytical Procedures: Methodology (1998a) The Rules Governing Medicinal Products in European Union, vol. 3A, 107-117.
21. Validation of Analytical Procedures: Definition and Terminology (1998b). The Rules Governing Medicinal Products in European Union, vol. 3A, 119-125.